Work

Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.2518

Authors: Sarina A. Piha-Paul, Marc Ryan Matrana, Gagandeep Brar, Miguel Villalona-Calero, Shirly Grynberg, Jonathan Cohen, Yakir Rottenberg, Iwona A. Lugowska, Michael Jon Chisamore, Eric Keith Rowinsky, Guy Cinamon, Pini Tsukerman, Keren Paz

Institutions: The University of Texas MD Anderson Cancer Center, Ochsner Health System, City of Hope, City Of Hope National Medical Center, Sheba Medical Center, Hebrew University of Jerusalem, Hadassah Medical Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: HORIZON EUROPE European Innovation Council

OpenAlex ID: W7162525655

Cites:

Cited by:

Related to: